Diabetic Autonomic Neuropathy and Left Ventricular Function
NCT05713396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 59
Last updated 2023-02-06
Summary
Purpose: To investigate the effect of Quinapril (Q) or Losartan (L) or their combination on definite Diabetic Autonomic Neuropathy (DAN) and left ventricular systolic and diastolic function (LVF) over a period of 4 years.
Patients-methods: Fifty-nine patients with definite DAN \[2 or more of the 4 Cardiovascular Reflex Tests (CRTs) were abnormal\] were studied for 4 years. Patients were randomly allocated in 3 groups receiving A, 20 mg Q, B, 100 mg L and C, 20 mg Q +100 mg L respectively. CRTs analyzed with Mean Circular Resultant (MCR), Valsalva index, 30:15 ratio and postural hypotension. LV function was investigated with radionuclide ventriculography (RNV) at rest. Ejection fraction was used to assess LV systolic function, while peak filling rate, first third filling fraction, and atrial contribution to ventricular filling were used to investigate LV diastolic function. CRTs and RNV were performed at baseline and after 4 years.
Conditions
Interventions
- DRUG
-
Quinapril
Per os
- DRUG
-
Losartan
Per os
- DRUG
-
Quinapril + Losartan
Per os
Sponsors & Collaborators
-
AHEPA University Hospital
lead OTHER
Principal Investigators
-
Triantafillos Didangelos, Professor · AHEPA University Hospital, Thessaloniki, Greece
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-01-01
- Primary Completion
- 2022-06-01
- Completion
- 2022-06-01
Countries
- Greece
Study Locations
More Related Trials
-
Effect of Empagliflozin on Ventricular Repolarization.
NCT04117763 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating DyNamic Myocardial Blood Flow QUantitation As a Cost Effective Care ModeL for DiabEtic Patients With Coronary Artery DiSease
NCT05343884 ·Status: RECRUITING ·Phase: NA
-
Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
NCT04320771 ·Status: TERMINATED ·Phase: PHASE1
-
RESynchronizaTiOn theRapy and bEta-blocker Titration
NCT02173028 ·Status: COMPLETED
-
Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
NCT06721442 ·Status: COMPLETED ·Phase: PHASE4
-
Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)
NCT01026090 ·Status: TERMINATED ·Phase: PHASE4
-
Dopamine in Acute Decompensated Heart Failure II
NCT01060293 ·Status: TERMINATED ·Phase: PHASE4
-
Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients
NCT02238457 ·Status: WITHDRAWN ·Phase: PHASE4
-
Dapagliflozin in Systemic Right Ventricle (DAPA-SERVE)
NCT05717257 ·Status: UNKNOWN ·Phase: PHASE4
-
Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
NCT00313443 ·Status: COMPLETED ·Phase: PHASE4
-
Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil
NCT01475123 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
NCT05350969 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
NCT01370629 ·Status: COMPLETED
-
Effect of Sodium Glucose Cotransporter 2 Inhibitiors on Left Ventricular Remodeling Among Diabetic and Non Diabetic Patients With Chronic Heart Failure
NCT06137430 ·Status: NOT_YET_RECRUITING
-
Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453
NCT02840565 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Trimetazidine in Diabetic Patients
NCT05556005 ·Status: UNKNOWN ·Phase: PHASE2
-
Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI Patients
NCT05957887 ·Status: RECRUITING ·Phase: PHASE3
-
Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)
NCT01481402 ·Status: COMPLETED ·Phase: NA
-
Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
NCT06759909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
NCT04792190 ·Status: COMPLETED ·Phase: PHASE4
-
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension
NCT00389675 ·Status: TERMINATED ·Phase: PHASE3
-
Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response
NCT05691959 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease
NCT04595370 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124 ·Status: COMPLETED ·Phase: PHASE3
-
Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging
NCT01021618 ·Status: COMPLETED ·Phase: NA